PAREXEL has appointed four executives to its senior leadership team, the Business Review Committee:·
- David Godwin, Senior Vice President, Global Business Development
- Michelle Graham, Senior Vice President and Chief Human Resources Officer
- Sy Pretorius, Senior Vice President and Chief Scientific Officer
- Joshua Schultz, Senior Vice President, Worldwide Head of PAREXEL Access
David joined PAREXEL in 1989 and is responsible for the business development efforts for many of the company’s services. He will continue to manage global business development initiatives.
Michelle joined the company in 2015 and is responsible for the design and launch of its people strategy, talent agenda and refined human resources operating model. She will continue to manage the company’s HR function, including talent acquisition, learning and development and organizational development as well as be responsible for the company’s Diversity and Inclusion programmes.
Sy joined PAREXEL in 1996 and previously held leadership roles in various countries. He serves as Chief Scientific Officer and works closely with clients to design and optimize drug and device development strategies as well as find, evaluate and purchase assets. He will continue to be responsible for the overall leadership of several service offerings, including PAREXEL’s global Early Phase business, Global Medical Services, Quantitative Clinical Development and Genomic Medicine.
Joshua (pictured) joined the company in 2005 and oversees the global Late Phase business, which provides clinical research services in the peri/post-approval phases, including IIIb/IV clinical trials, observational research, market access, medical communications and patient safety services. He will continue to lead PAREXEL Access.
